Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Reata Pharmaceuticals
Biotech
Biogen CEO said no risky deals in 2023. Now he’s ready to be bold
While Biogen’s pharma peers are hunting for late-stage assets with little risk, CEO Chris Viehbacher wants to bring in more early-stage medicines.
Annalee Armstrong
Aug 1, 2024 10:34am
Top 10 smartest deals in biopharma
Jun 24, 2024 6:00am
Biogen's top dealmaker is keen on rare disease meds
Mar 5, 2024 10:20am
Amgen poaches Moderna CMO—Chutes & Ladders
Jun 16, 2023 9:30am
Reata, Kyowa Kirin ax bardoxolone, ending 13-year saga
May 10, 2023 10:22am
FDA scraps AdComm for Reata's rare disease candidate
Oct 14, 2022 9:30am
